The role of NF-κB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells

Journal of Immunology

Volumn 166, Issue 9, 2001, Pages 5337-5345

  Franco, A V ^a   Xu Dong Zhang, ^a   Van Berkel, E ^a   Sanders, J E ^a   Xi Yi Zhang, ^a   Thomas, W D ^a   Nguyen, T ^a   Hersey, P ^a  

^a David Maddison Building ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLASMID VECTOR; PROTEASOME INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MEASUREMENT; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0035340285     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.9.5337     Document Type: Article

References (49)

1. Apoptosis by death factor
2. Deciphering the apoptotic pathway: All roads lead to death
3. TRAIL: A molecule with multiple receptors and control mechanisms
4. Identification and characterization of a new member of the TNF family that induces apoptosis
5. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
6. Identification of a ligand for the death-domain-containing receptor Apo3
7. The receptor for the cytotoxic ligand TRAIL
8. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB
9. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
10. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
11. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
12. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
13. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
14. Characterization of two receptors for TRAIL
15. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling
16. A novel receptor for Apo2L/TRAIL contains a truncated death domain
17. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
18. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
19. IAP family proteins: Suppressors of apoptosis
20. The prosurvival Bcl-2 homolog Bf1-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis
21. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells
22. Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand
23. Efficient adenoviral transfer of NF-κB inhibitor sensitizes melanoma to tumor necrosis factor-mediated apoptosis
24. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
25. Expression of a dominant-negative mutant inhibitor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo
26. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas Ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells
27. Relation of TRAIL receptor and FLIP expression to TRAIL induced apoptosis of melanoma
28. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells
29. Expression of the co-stimulatory molecule CD40 on melanoma cells
30. CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95)
31. Polymerase chain reaction detection of melanoma cells in the circulation: Relation to clinical stage, surgical treatment, and recurrence from melanoma
32. N- and C-terminal sequences control degradation of MAD3/I κBα in response to inducers of NF-κB activity
33. Functional analysis of TRAIL receptors using monoclonal antibodies
34. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB
35. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
36. Detection of intracellular cytokines by flow cytometry
37. Analysis of flow cytometry data
38. Novel flow cytometric method for quantifying nuclear binding of the transcription factor nuclear factor κB in unseparated human monocytes and polymorphonuclear cells
39. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
40. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei
41. Proteasome inhibitors; a novel class of potent and effective antitumor agents
42. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
43. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity
44. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
45. Constitutive nuclear factor-κB-Re1A activation is required for proliferation and survival of Hodgkin's disease tumor cells
46. Activation of nuclear factor-κB in human metastatic melanoma cells and the effect of oxidative stress
47. + T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase
48. Enhanced degradation of I-κBα contributes to endogenous activation of NF-κB in Hs294T melanoma cells
49. Mechanisms of resistance of normal cells to TRAIL-induced apoptosis vary between different cell types